Sun Pharmaceutical Industries Ltd.

BSE: 524715 | NSE: SUNPHARMA
Large Cap | Pharmaceuticals & Drugs
1634.40
21.85 (1.35%)
< Home < Back

Sun Pharmaceutical gains on concluding Opiates business acquisition in Australia

Date: 01-09-2015

Sun Pharmaceutical Industries is currently trading at Rs. 904.80, up by 7.10 points or 0.79% from its previous closing of Rs. 897.70 on the BSE.

The scrip opened at Rs. 889.00 and has touched a high and low of Rs. 908.90 and Rs. 883.40 respectively. So far 46,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 748.15 on 26-Sep-2014.

Last one week high and low of the scrip stood at Rs. 916.50 and Rs. 864.55 respectively. The current market cap of the company is Rs. 2,17,722.00 crore.

The promoters holding in the company stood at 54.71% while Institutions and Non-Institutions held 31.51% and 13.78% respectively.

Sun Pharmaceutical Industries has begun the integration of its Opiates business in Australia following the successful completion of this acquisition from GSK (announced in March 2015). This acquisition fortifies Sun Pharma’s global position with two Opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.

Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialized team to drive business growth.

The Opiates acquisition allows Sun Pharma to significantly expand its narcotics raw material (NRM) market share; enhance Opiate Alkaloids portfolio and depth in Global opiates market and strengthen its strategic position in the global Opiates business.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.